QIAGEN has received emergency use authorization (EUA) from the US FDA for its QIAreach SARS CoV-2 Antigen Test, which is designed for environments requiring a high volume of fast and accurate test results. The rapid portable test can detect SARS-CoV-2 antigen in patients with active infections in 2 to 15 minutes and can process an average of around 30 swab samples per hour, providing digital test results that do not require subjective interpretation. Clinical studies have shown the test to have a sensitivity of at least 80% and a specificity of 98%. The test uses QIAGEN’s UL-certified eHub, a portable reader with backup battery power that can be operated remotely from main power for up to 8 hours. The test has the capacity to analyze nasal and nasopharyngeal swab samples from up to eight symptomatic patients, simultaneously. Using this test in combination with QIAreach Anti-SARS-CoV-2 Total Test enables labs to run antigen tests and antibody tests at the same time.